AFP2 天
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
Scientific American1 天
What Is Journavx, the New Opioid-Free Painkiller from Vertex?
The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...
Nursing in Practice2 天
CPD: Preventing diabetes complications
GP Dr Roger Henderson provides an overview of the chronic complications of diabetes and the key preventive measures ...
GlobalData on MSN2 天
FDA approves Vertex’s acute pain treatment Journavx
The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults ...
Too Old to Operate4 天
Association of hs-cTnT With Diabetic Lower Extremity Disease
The following is a summary of “Correlation between high-sensitivity cardiac troponin levels in diabetic patients’ serum and ...
Many cancer patients experience nerve pain from chemo
Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.
Zacks.com on MSN2 天
VRTX Gets FDA Nod for Non-Opioid Pain Drug Journavx, Shares Up
The FDA approves Vertex's non-opioid oral pain signal inhibitor, Journavx, for treating adults with moderate-to-severe acute pain. Shares rise.